Introduction
Gliomas are common brain tumors that occur as ependymomas, oligodendrogliomas, and astrocytomas of WHO grades I-IV (1). Glioblastoma (WHO grade IV), the most malignant and common form of glioma, is characterized by microvascular proliferation and morphologically abnormal tumor vessels (2) . The aberrant tumor vasculature is permeable and dysfunctional, and contributes to patient morbidity by inducing vasogenic edema in the brain (3) . Poor vascular perfusion leads to intermittent hypoxia and a low pH in the tumor microenvironment, and prevents efficient drug delivery, thereby affecting the response to chemotherapy and radiation (4) . Therefore, it has been proposed that therapeutic strategies that normalize the tumor vessels may improve the response to conventional cancer therapy (5) . Antiangiogenic therapy neutralizing VEGF, or blocking signaling through its cognate receptor VEGFR2, has been approved as second-line treatment for glioblastoma owing to prolonged progression-free survival, although no increase in overall survival is observed (6) . Several other angiogenic factors are expressed in glioma and may contribute to tumor angiogenesis and/or resistance to antiangiogenic therapy, including TGF-β2 and pleiotrophin (7, 8) . An increased understanding of the mechanisms leading to vascular abnormalities in glioblastoma and its consequences for the tumor microenvironment is necessary to successfully target the tumor vessels. One important step toward this goal is to map proteins specifically expressed in glioblastoma vessels and investigate their role in tumor angiogenesis.
Through laser-capture microdissection of tumor vessels followed by microarray analysis of gene expression, we have previously distinguished a transcriptional signature consisting of 95 genes differentially expressed in human glioblastoma vessels (7) . Among these genes, we identified the single-pass transmembrane glycoprotein CD93 as significantly upregulated in glioblastoma vessels compared with vessels in low-grade glioma and in normal brain. CD93 is predominantly expressed in endothelial cells and consists of an extracellular part including a C-type lectin domain, 5 EGF-like repeats, a serine/threonine-rich mucinlike domain, a transmembrane domain, and a short cytoplasmic domain harboring a binding site for moesin. The extracellular domain can be shed and released during inflammation, and soluble CD93 has been proposed to have a proangiogenic effect through its EGF-like repeats (9, 10) .
We have previously demonstrated that CD93 is required for tubular morphogenesis, migration, and adhesion of endothelial cells and plays a key role in organizing the endothelial cytoskeleton and cell junctions (11) . Consistent with this, an antibody targeting CD93 inhibited formation of tubular structures (12) . Importantly, we found that a high expression of CD93 in tumor vessels correlated with shorter survival of patients with astrocytomas of WHO grades III-IV. We also observed that growth of orthotopically implanted syngeneic GL261 glioma was inhibited in CD93 -/-Tumor angiogenesis occurs through regulation of genes that orchestrate endothelial sprouting and vessel maturation, including deposition of a vessel-associated extracellular matrix. CD93 is a transmembrane receptor that is upregulated in tumor vessels in many cancers, including high-grade glioma. Here, we demonstrate that CD93 regulates β 1 integrin signaling and organization of fibronectin fibrillogenesis during tumor vascularization. In endothelial cells and mouse retina, CD93 was found to be expressed in endothelial filopodia and to promote filopodia formation. The CD93 localization to endothelial filopodia was stabilized by interaction with multimerin-2 (MMRN2), which inhibited its proteolytic cleavage. The CD93-MMRN2 complex was required for activation of β 1 integrin, phosphorylation of focal adhesion kinase (FAK), and fibronectin fibrillogenesis in endothelial cells. Consequently, tumor vessels in gliomas implanted orthotopically in CD93-deficient mice showed diminished activation of β 1 integrin and lacked organization of fibronectin into fibrillar structures. These findings demonstrate a key role of CD93 in vascular maturation and organization of the extracellular matrix in tumors, identifying it as a potential target for therapy.
between MMRN2 and CD93 occurs abluminally in proximity to extracellular matrix (arrowheads in Supplemental Figure 1 , C and D). Similarly, MMRN2 was highly expressed in murine GL261 glioma vasculature, colocalizing with CD93 ( Figure 1E ). A significantly lower basal expression of MMRN2 colocalizing with CD93 was observed in the brain vasculature adjacent to the GL261 tumor ( Figure 1F and quantification in Figure 1G ).
CD93 colocalizes with MMRN2 during retinal angiogenesis and regulates filopodia formation and vessel sprouting. To further understand the role of CD93 in sprouting angiogenesis, we analyzed the developing vasculature in mouse retina. CD93 was expressed in the sprouting front of the postnatal day 6 (P6) mouse retinas, including the filopodia protrusions, colocalizing with the endothelial marker isolectin B4 (Figure 2A ). MMRN2 colocalized with CD93 in the retinal plexus and sprouting front, but colocalization was not detectable in filopodia extensions (high magnification, Figure 2 , A and B). Instead, MMRN2-positive signals were found in the extracellular matrix surrounding the filopodia at the vascular front (arrowheads, Figure 2A ) and within the vascular plexus (arrowheads, Figure 2B ). This indicates that MMRN2 is not present within the filopodia, but interacts with CD93 in filopodia after being secreted. To investigate whether loss of CD93 affects retinal angiogenesis, we analyzed P6 retinas from CD93-deficient (CD93 -/-) mice and WT littermates. The radial expansion of the vascular plexus was similar in CD93 -/-and WT retinas ( Figure 2C , quantified in Figure 2F ). However, the mean length of the sprouts in the angiogenic front was significantly reduced in the CD93 -/-retinal vasculature in comparison with WT littermates ( Figure 2D , quantified in Figure 2G ). In addition, a significant reduction in filopodia protrusions was observed in CD93 -/-mice compared with WT mice ( Figure 2E , quantified in Figure 2H ). No differences were observed when the sprout length and the number of filopodia were compared between WT and CD93 heterozygous mice (CD93 +/-; Figure 2 , G and H). The importance of CD93 in filopodia formation was further analyzed through siRNA-mediated knockdown of CD93 in human dermal blood endothelial cells (HDBECs). In line with a reduced number of filopodia in CD93 -/-P6 retinas, sparsely seeded CD93 siRNA-treated endothelial cells formed fewer filopodia than control cells (Supplemental Figure 2, A and B) . These data indicate that CD93 regulates filopodia formation and the extension of endothelial sprouts during angiogenesis.
MMRN2 protects CD93 from proteolytic cleavage. To investigate whether the interaction between CD93 and MMRN2 affects the expression or stability of either protein, CD93 and MMRN2 mRNA and protein levels were examined in HDBECs after siRNA-mediated knockdown of CD93 or MMRN2. Transfection of endothelial cells with siRNA targeting CD93 reduced CD93 mRNA expression and protein level by approximately 95% compared with controls ( Figure 3A ). An equally high knockdown efficiency was obtained using siRNAs against MMRN2 ( Figure 3B ). siRNA-mediated knockdown of CD93 did not affect MMRN2 mRNA or protein levels ( Figure 3 , C and E). Similarly, CD93 mRNA levels were not affected by MMRN2 downregulation ( Figure 3D ). However, Western blot analysis revealed a significant reduction of CD93 protein levels in siMMRN2-treated cells compared with controls ( Figure  3F ). This suggests that MMRN2 affects CD93 protein stability but not CD93 gene expression. mice, and that this was associated with decreased tumor vessel functionality (11) . These observations indicate an important role of CD93 during tumor angiogenesis in glioma. CD93 has been shown to interact with moesin via its cytoplasmic domain and with β-dystroglycan in the extracellular matrix (13, 14) . However, the mechanisms through which CD93 affects sprouting angiogenesis and the architecture of tumor vessels are still largely unknown.
Here, we demonstrate that CD93 localizes to filopodia during angiogenesis and is specifically expressed in tip cells in endothelial sprouts formed by embryoid bodies. CD93 localization in filopodia is stabilized by interaction with the extracellular matrixbinding protein multimerin-2 (MMRN2), which anchors CD93 to fibronectin and inhibits its proteolytic cleavage. CD93 colocalizes with activated β 1 integrin chain in endothelial cells, and is required for full β 1 integrin activation and fibronectin fibrillogenesis in vitro. Consistent with this, the fibronectin network connected to the tumor vasculature is disrupted in intracranially implanted gliomas in CD93 -/-mice. Taken together, our data support a key role of CD93 and MMRN2 in fibronectin fibrillogenesis, which is crucial for tumor angiogenesis and vascular integrity. Most importantly, we define a new mechanism of modulation of integrin activity during cancer angiogenesis.
Results

CD93 and MMRN2 interact in human endothelial cells and colocalize in tumor vessels.
To investigate the mechanisms through which CD93 regulates vascular function, interacting proteins were identified by coimmunoprecipitation from human endothelial cell protein extracts using a monoclonal anti-CD93 antibody followed by mass spectrometry. Analysis of 5 independent experiments identified the endothelial-specific secreted matrix-binding protein MMRN2 as a potential CD93-binding molecule. MMRN2 was identified in all 5 CD93 coimmunoprecipitated samples and never in samples coimmunoprecipitated with IgG. The CD93-MMRN2 interaction was confirmed by Western blot analysis of CD93 coimmunoprecipitated samples using antibodies directed against MMRN2 ( Figure 1A ). In situ proximity ligation assay (PLA) technology was used to verify CD93-MMRN2 interaction in human endothelial cell monolayers. Positive PLA signals indicating formation of CD93-MMRN2 complexes were homogeneously distributed in endothelial cells ( Figure 1B ). The specificity of the PLA assay was confirmed by quantification of CD93-MMRN2 PLA signals per cell, comparing with signals in negative controls ( Figure 1C ).
CD93 is highly expressed in the tumor vasculature of human high-grade gliomas (15) as well as in tumor vessels in the orthotopic murine GL261 glioma model (11) . To determine whether the observed interaction between CD93 and MMRN2 is likely to occur in tumor vessels, we examined the expression pattern of MMRN2 in tumors. MMRN2 was expressed in CD31-positive tumor vessels of human glioblastoma (grade IV glioma), colocalizing with CD93 expression ( Figure 1D ). Analysis of y-z 3D stack of the grade IV glioma vessels revealed that MMRN2 and CD93 were expressed at the abluminal side of the CD31-positive glioblastoma vessels (arrowheads in Supplemental Figure 1 , A and B, respectively; supplemental material available online with this article; https:// doi.org/10.1172/JCI97459DS1), indicating that the interaction jci.org Volume 128 Number 8 August 2018
of MMRN2 in CD93 degradation, using proteasome and lysosome inhibitors. Inhibition of either proteasomal degradation by 20 μM lactacystin during 8 hours or lysosomal degradation using 10 mM NH 4 Cl during 18 hours resulted in accumulation of CD93 protein in controls, indicating that CD93 is degraded through both proteasome-and lysosome-dependent mechanisms (Supplemental Figure 3 , A and B). However, the siMMRN2-mediated decrease in CD93 protein level was not restored to control levels by treatment with either proteasome or lysosome inhibitors. These results indicate that the reduction of CD93 protein levels observed after MMRN2 knockdown is not due to enhanced intracellular protein degradation. CD93 can be cleaved from the plasma membrane in response to inflammatory conditions, releasing a soluble CD93 fragment To determine whether MMRN2 regulates CD93 protein stability in endothelial cells, protein synthesis was blocked with cycloheximide (CHX) treatment over a time course of 0, 30, 60, and 240 minutes in siMMRN2 and control cells, and CD93 protein levels were determined by Western blot analysis. A gradual reduction of CD93 over time was observed in the control conditions (Mock and siCtrl) in response to CHX treatment, indicating a timedependent turnover of CD93 protein ( Figure 3G and graph in Figure 3H ). When MMRN2 expression was knocked down by siRNA treatment, the reduction of CD93 protein levels was accelerated ( Figure 3 , G and H). These results indicate that the interaction with MMRN2 stabilizes CD93 protein in endothelial cells.
To further characterize the mechanism by which MMRN2 regulates CD93 protein levels, we assessed the possible impact (11) . To investigate whether the interaction with MMRN2 decreases cleavage of CD93 in endothelial filopodia, the subcellular localcontaining the EGF-like domain (9) . We therefore assessed whether the interaction with MMRN2 affected shedding of CD93 from endothelial cells. Conditioned media from control cells and siMMRN2-treated cells were concentrated and analyzed by Western blot to detect soluble CD93 ( Figure 3I) . Notably, the level of soluble CD93 was increased more than 60% in the conditioned medium derived from siMMRN2-treated cells as compared with the soluble CD93 levels in that derived from control cells (Figure To further analyze the localization of CD93 during endothelial cell migration, an in vitro wound healing assay was used, and the localization of CD93 in the leading edge of migrating cells was analyzed by confocal microscopy. A strong CD93 staining was consistently detected in the migrating front and filopodia of control endothelial cells ( Figure 4B ). In contrast, only low levels of CD93 were observed at the migration front in MMRN2-silenced cells. The CD93-positive signal in siMMRN2-treated endothelial cells was mainly located in the perinuclear region ( Figure 4B ).
MMRN2 is an extracellular matrix protein secreted by endothelial cells. Therefore, we analyzed whether MMRN2 produced and secreted by control cells can rescue CD93 localization to endothelial filopodia and the migrating front in siMMRN2-transfected cells. The rescue experiment was performed using cell culture inserts. Control cells and siMMRN2 cells were initially cultured in separate wells until confluence. When the culture insert was removed, control and siMMRN2-treated endothelial cells were allowed to migrate for 6 hours, sharing the same culture media (Supplemental Figure 4C) . CD93 was strongly localized in the migrating front and filopodia when control endothelial cells were cocultured on each side of the insert. However, a significant reduction of CD93-positive signal was detected in the migrating front when siMMRN2-treated cells were present on both sides of the insert ( Figure 4C ). Coculture with control cells restored CD93 levels in the migrating front of MMRN2-silenced cells ( Figure 4D ). CD93-positive signals in the migrating front (area delimited by dotted line in Figure 4 , C and D) were quantified, showing a complete rescue of CD93 levels in MMRN2 siRNA-treated endothelial cells when cocultured with control endothelial cells ( Figure 4E ). Thus, MMRN2 secreted by control cells can stabilize CD93 in the migrating front and filopodia of MMRN2-deficient endothelial cells. This indicates that CD93 in filopodia interacts with MMRN2 in the extracellular matrix. This result was further confirmed by costaining of CD93 and MMRN2 during migration. MMRN2 colocalized with CD93 in the migrating front in the control condition (arrowheads in the high-magnification picture of siCtrl, Figure 4F ). Knockdown of MMRN2 resulted in a loss of CD93 in the migrating front (siMMRN2_3 panel, Figure 4F ). CD93 localization to filopodia is rescued by treatment of siMMRN2-treated endothelial cells with conditioned medium (CM) derived from control cells. In association, we observed that MMRN2, derived from conditioned medium, bound to endothelial filopodia on siMMRN2-treated cells (arrowheads in siMMRN2_3+siCtrl CM, Figure 4G ). As a functional readout, we quantified endothelial migration using the scratch wound assay. Downregulation of MMRN2 (siMMRN2_3 and siM-MRN2_6, black dashed lines, Figure 4H ) significantly impaired migration at 6 hours after wounding in comparison with control cells (Mock and siCtrl, solid black lines, Figure 4H ). This inhibitory effect was reverted by culturing of siMMRN2 cells in conditioned media from control cells containing secreted MMRN2 (siMMRN2+Mock or siCtrl CM, red dashed lines, Figure 4H ).
CD93 is predominantly expressed in tip cells, while MMRN2 is distributed throughout endothelial sprouts in embryoid bodies.
We used the embryoid body (EB) model of angiogenesis to examine the expression patterns of CD93 and MMRN2 during blood vessel formation. EBs are aggregates of embryonic stem (ES) cells that can be induced to differentiate into various cell types and, when cultured in the presence of VEGF, recapitulate sprouting angiogenesis (16) . EBs were grown on a 2-dimensional (2D) glass slide surface or in a 3D collagen I matrix and stimulated with VEGFA to induce sprouting angiogenesis. Immunofluorescent staining of EBs cultured on 2D glass slide surfaces showed that CD93 was exclusively localized in the sprouting front of the vascular plexus with high levels detected in endothelial filopodia ( Figure 5A ). In contrast, MMRN2 expression was observed throughout the vascular network and colocalized with CD93 in the sprouting front (high magnification in Figure 5A ). MMRN2 was specifically expressed in endothelial cells within the retina, consistent with previous publications (17, 18) . A similar localization of CD93 and MMRN2 was observed in sprouting vessels formed by EBs cultured in a 3D collagen I matrix ( Figure 5B ). CD93 was mainly observed in the tip cells of endothelial sprouts, whereas MMRN2 was expressed both in the tip and in the stalk cells, colocalizing with CD93 in the tip cell filopodia ( Figure 5B ). Consistent with a role of secreted MMRN2 in interacting with and stabilizing CD93 during endothelial migration and sprouting, deficient sprouting in 2D shMMRN2 EBs ( Figure 5G ) could be rescued by coculturing with control EBs ( Figure 5 , G and H, quantified in Figure 5I ). In contrast, endothelial sprouting in CD93-deficient EBs was not rescued by coculturing with control EBs, consistent with a key role of cell surface-bound CD93 in this context ( Figure 5 , G and H, quantified in Figure 5I ). These results support an important role of CD93 and MMRN2 during sprouting angiogenesis.
CD93 or MMRN2 downregulation disrupts fibronectin fibrillogenesis in endothelial cells. Costaining of CD93 and MMRN2 in confluent endothelial cells showed colocalization of these proteins along fibrillar structures distributed on the endothelial monolayer ( Figure 6A ). CD93 did not colocalize with filamentous F-actin or other cytoskeletal proteins, including tubulin or vimentin, in confluent endothelial cells (Supplemental Figure 6, A-C) . Instead, a jci.org Volume 128 Number 8 August 2018 Costaining with vesicular markers revealed that CD93 colocalized with caveolin-1-coated vesicles in endothelial cells, while MMRN2 was found partially associated with vWF-positive vesicles (Supplemental Figure 6 , D and E). Our data suggest that the interaction between CD93 and MMRN2 occurs in the cell membrane-extracellular matrix interface.
Fibronectin is a major component of the extracellular matrix and is essential for sprouting angiogenesis and cell migration (19) . Therefore, we investigated whether the interaction of CD93 deeper characterization of the subcellular distribution of CD93 and MMRN2 revealed that both proteins colocalize with fibronectin fibers (siCtrl in Figure 6 , B and C). The colocalization between CD93 and fibronectin was dramatically inhibited in MMRN2-silenced endothelial cells (siMMRN2_3 in Figure 6B ). In contrast, downregulation of CD93 did not affect the colocalization between MMRN2 and fibronectin fibers (siCD93_1 in Figure 6C ). These results indicate that MMRN2 is required for CD93 interaction with fibronectin in extracellular matrix. we observed reduced FAK activation, monitored as Y397-phosphorylated FAK (p-FAK), in endothelial cells treated with siRNA targeting either CD93 or MMRN2. We detected high levels of p-FAK in the focal adhesion sites at the leading edge of migrating control endothelial cells, while a striking reduction of p-FAK levels were found in the migrating front of endothelial cells silenced for either CD93 or MMRN2 ( Figure 7E , quantified in Figure 7F ). These data indicate that CD93 interacts with α 5 β 1 integrin and modulates its activation, leading to the phosphorylation of the downstream molecule FAK, and inducing fibronectin fibrillogenesis required for cell migration. The extracellular matrix protein MMRN2 stabilizes CD93 and thereby enhances the activation of α 5 β 1 integrin. The proposed mechanism through which the CD93-MMRN2 complex interacts with integrins and fibronectin, thus affecting endothelial cell dynamics, is depicted in Figure 7G . β 1 Integrin is critical for vessel growth and maturation and is indispensable for efficient endothelial sprout formation (23) . Given the significant inhibition in endothelial sprouts and endothelial filopodia observed in CD93 -/-retinas ( Figure 2 , D and E), integrin activation and fibronectin fibrillogenesis was assessed during developmental angiogenesis in P6 WT and CD93 -/-mouse retinas. Consistent with a key role of CD93 in β 1 integrin activation, a dramatic inhibition of the active form of β 1 integrin (recognized by the 9EG7 antibody) was observed in the sprouting front and filopodia of CD93 -/-retinas compared with WT mice ( Figure 8A ). In addition, fibronectin staining showed disruption of fibronectin fibers in the sprouting front and filopodia of CD93 -/-retinas ( Figure 8B ).
CD93 and MMRN2 expression correlates with increased fibronectin deposition in human glioma vessels.
Fibronectin fibrillogenesis is a known feature of tumor angiogenesis. To determine whether CD93 is coexpressed with MMRN2 and fibronectin fibrils in human glioma vessels, we analyzed the fraction of blood vessels positive for MMRN2 ( Figure 9A ) and fibronectin ( Figure 9B ) in glioma tissue microarrays, containing a total of 235 samples of human control brain and WHO grade II-IV glioma tissues, and correlated the scores with our previous scoring of CD93 expression (11) . Since MMRN2 and fibronectin were heterogeneously expressed in tumor vessels, a semiquantitative scoring method was used based on the proportion of positive vessels in each core. Similar to our previous observation that CD93 expression is increased in the vasculature of human high-grade glioma (HGG) (11), MMRN2 and fibronectin were significantly elevated in WHO grade III and IV glioma compared with low-grade glioma (LGG; WHO grade II) or control brain samples ( Figure 9, C and D) . When correlating the scoring of MMRN2 staining with the scoring of CD93 staining in the same tissue microarray cores, we found that high levels of CD93 corresponded to significantly higher levels of MMRN2 in samples from LGG ( Figure 9E ) and HGG ( Figure  9H ). Similar results were obtained when we correlated fibronectin scores with CD93 scores in the vessels of LGG ( Figure 9F ) and HGG ( Figure 9I ). HGG samples with high levels of vascular MMRN2 showed significantly higher levels of fibronectin associated with the vessels (Figure 9J ). No significant association was found between fibronectin and MMRN2 in LGG ( Figure 9G ). These results indicate that CD93, fibronectin, and MMRN2 are coexpressed in tumor vessels in glioma, and that the levels of these with MMRN2 affects the organization of fibronectin fibrils. Control endothelial cells grown on gelatin formed a dense fibronectin matrix and a well-organized fibrillar network (Mock and siCtrl in Figure 6D ). However, downregulation of either CD93 or MMRN2 in endothelial cells induced a disruption in the fibronectin fibrillar network as compared with controls (siCD93 and siMMRN2 in Figure 6D ). In contrast, fibronectin gene expression in siCD93 and siMMRN2 cells was similar to that in controls ( Figure 6E ). These results indicate that CD93 and MMRN2 are important for the organization of fibronectin into fibrillary structures, but that they do not regulate fibronectin expression in endothelial cells. Consistent with these results, decreased fibronectin fibrillogenesis was observed in brain endothelial cells isolated from CD93 -/-mice compared with those isolated from WT mice ( Figure 6F ). Disrupted fibronectin fibrillogenesis was restored by lentiviral transfection with a WT CD93 construct in endothelial cells silenced for endogenous CD93 ( Figure 6G) . A similar rescue effect on fibronectin fibrillogenesis was observed when siMMRN2 cells were cultured in conditioned medium derived from control cells ( Figure 6H ). These data point out a novel role of MMRN2 and CD93 interaction in regulating organization of fibronectin in extracellular matrix.
Knockdown of CD93 or MMRN2 impairs β 1 integrin activation and phosphorylation of focal adhesion kinase in endothelial cells.
Integrins are transmembrane proteins with a well-described function in the regulation of cell-matrix adhesion, extracellular matrix organization, and cell migration (20) . In particular, α 5 β 1 integrin plays a key role in the regulation of fibronectin fibrillogenesis and extracellular matrix deposition (21) . We therefore investigated whether β 1 integrin activity was altered in CD93-or MMRN2-downregulated cells. β 1 Integrin activation was assessed by immunofluorescent staining using an antibody that specifically recognizes the active conformation of β 1 integrin (clone 12G10). A striking reduction of active β 1 integrin was observed in endothelial cells when either CD93 or MMRN2 was silenced ( Figure 7, A and  B) . This reduction in β 1 integrin activation was confirmed by Western blot analysis, indicating that CD93 and MMRN2 affect integrin activation rather than expression (Supplemental Figure 7A) . The important role of CD93 in regulating β 1 integrin activation was confirmed in brain endothelial cells isolated from CD93 -/-and WT mice, showing a striking reduction in β 1 integrin activation in the absence of CD93 (Supplemental Figure 7B) . β 1 Integrin can interact with several integrin α subunits in endothelial cells, and the main receptor for fibronectin is the α 5 β 1 integrin. CD93 colocalized with α 5 β 1 integrin in confluent HDBECs and in filopodia of sparsely seeded endothelial cells (arrowheads in Figure 7C and Supplemental Figure 7C ). Costaining with the 12G10 antibody revealed colocalization between CD93 and activated β 1 integrin in endothelial cells. α v β 3 Integrin can also bind to fibronectin in endothelial cells, but we did not observe colocalization between CD93 and α v β 3 integrin ( Figure 7C ). The CD93-α 5 β 1 interaction was further confirmed by PLA showing statistically significant interaction between CD93 and α 5 β 1 as well as CD93 and active β 1 integrin ( Figure 7D ).
Focal adhesion kinase (FAK) is activated downstream of integrin activation and plays a key role in focal adhesion turnover as well as cytoskeleton organization and cell migration (22) . In line with a requirement of CD93 and MMRN2 for full β 1 integrin activation, jci.org Volume 128 Number 8 August 2018 our previous report, the mean GL261 tumor area was significantly reduced in CD93 -/-mice as compared with WT mice ( Figure 10E  and ref. 11) . These results indicate a nonredundant role of CD93 in promoting β 1 integrin activation and fibronectin fibrillogenesis during glioma angiogenesis. A 3D volume reconstruction of fibronectin deposition and CD31-positive vessels in GL261 tumors revealed that fibronectin fibrils are consistently associated with blood vessels (arrowheads Figure 10F) . Thus, our data show that fibronectin matrix is mainly deposited and organized in fibrillary structures by endothelial cells in GL261 tumors, and indicate that CD93 expression is critical for correct organization of fibronectin during tumor angiogenesis.
Discussion
CD93 is a member of group XIV in the C-type lectin superfamily, which also includes thrombomodulin, CLEC14A, and endosialin, all of which are highly expressed in tumor vessels (24) (25) (26) . While CD93 and CLEC14A are expressed in tumor endothelial cells, endosialin is mainly expressed in pericytes (11, 24, 27) . Notably, CD93, along with CLEC14A, was recently included as one of the top 20 genes in a common angiogenesis signature of human tumors (28) . Because of a high expression of group XIV C-type lectins in human cancer during tumor angiogenesis, these proteins have emerged as potential targets for therapy. However, little is known regarding the mechanisms through which they regulate vessel formation in cancer.
MMRN2 is an endothelial cell-specific member of the EMIL-IN family, secreted homotrimeric glycoproteins that assemble into multimers in the extracellular matrix (29) . MMRN2 was previously found to be upregulated in tumor vessels in experimental cancer models, and to bind to CLEC14A (30, 31) . Our study shows that MMRN2 is a key interaction partner of CD93 during tumor angiogenesis. We found that MMRN2 expression correlates to WHO grade in glioma, and that the level is considerably lower in normal brain vessels. Gliomas with high vascular expression of CD93 express higher levels of MMRN2 and show enhanced fibronectin proteins are increased in higher malignancy grades, suggesting a functional role of the CD93-MMRN2-fibronectin complex during tumor angiogenesis.
CD93 is essential for β 1 integrin activation and fibronectin fibrillogenesis in GL261 tumor vessels. To determine whether CD93 is required for efficient β 1 integrin activation and fibronectin fibrillogenesis during tumor angiogenesis, we analyzed tumor vessels in intracranial GL261 gliomas in WT and CD93 -/-mice. By immunofluorescence staining using an antibody that specifically recognizes the active form of β 1 integrin (clone 9EG7), we found that β 1 integrin was highly activated in tumor vessels (Wild-type in Figure  10A ). In contrast, a dramatic reduction of β 1 integrin activation was observed in GL261 tumor vessels in CD93 -/-mice (CD93 -/-in Figure 10A ). In normal vessels adjacent to the tumor site, β 1 integrin activation was low or absent in both WT and CD93 -/-mice (Supplemental Figure 8A) .
Immunostaining revealed an abundant deposition of fibronectin in the GL261 tumor tissue in WT mice, predominantly associated with the tumor vessels ( Figure 10B ). Notably, a substantial reduction of fibronectin deposition was found in the CD93 -/-GL261 tumor, and disrupted fibronectin fibers were observed associated with the tumor vasculature ( Figure 10B) . Quantification of the fibronectin signal revealed a significant reduction of fibronectin deposition in GL261 tumors from CD93 -/-mice compared with tumors from WT mice ( Figure 10, C and D) . No obvious differences in fibronectin deposition were found in the normal vasculature of CD93 -/-mice compared with WT mice, and fibronectin levels in normal vessels were considerably lower than those in tumor vessels (Supplemental Figure 8B) . Fibronectin gene expression analysis showed a significant upregulation of fibronectin in tumor tissue as compared with nontumor brain tissue, and no differences were found when WT and CD93 -/-mice were compared (Supplemental Figure 8C ). Fibronectin expression was considerably higher in brain endothelial cells than in GL261 cells, suggesting a main contribution of the vasculature in fibronectin production in this tumor model (Supplemental Figure 8D) . Consistent with by MMPs (35) . Similarly, MMRN2 can be processed by MMP-9, which has been suggested to regulate endothelial sprouting (36). Fibronectin was not found to directly interact with CD93 in our coimmunoprecipitation/mass spectrometry analysis. Our data are consistent with CD93 binding to MMRN2 during formation of the angiogenic sprout, enabling its interaction with fibronectin and subsequent fibrillogenesis as further discussed below. Our data demonstrate a nonredundant role of CD93 in orchestrating integrin activation and fibronectin organization during tumor angiogenesis. However, the common binding to MMRN2 by proteins of the group XIV C-type lectin superfamily indicates a network of deposition. While the manuscript of this article was being finalized, the CD93-MMRN2 interaction was confirmed by 2 studies demonstrating direct binding of MMRN2 with CD93 and endosialin (32, 33) . Interestingly, CD93 and CLEC14A interact with the same part of MMRN2, suggesting that CD93 and CLEC14A may compete for binding. Shedding of CLEC14A from the endothelial cell surface catalyzed by rhomboid-like 2 protein is known to inhibit migration of endothelial cells (34) . We show that MMRN2 protects CD93 from cleavage of its extracellular domain. The protease responsible for shedding of CD93 in endothelial cells has not yet been identified. In human myeloid cells CD93 is cleaved ronment, leading to perturbed tip and stalk cell conversion (42) . Indeed, we have previously found that pleiotrophin promotes vascular abnormalities associated with an exceptionally high perivascular deposition of VEGF (8) . Targeting molecules important for tip/stalk conversion may affect angiogenesis. In CD93 -/-mice, there are fewer filopodia in the sprouting front during vascular development in the retina, suggesting that CD93 is important for tip cell behavior. However, we did not detect any difference in the sprouting distance. This may suggest either that there is a surplus of filopodia formed in the retina, or that compensatory mechanisms rescue endothelial sprouting despite decreased filopodia formation. Nevertheless, our data are consistent with an important role of CD93 in filopodia formation during angiogenesis. coregulation and mutual interaction during angiogenesis, which is an interesting area for further study.
In the embryoid body model of vascular development, CD93 was exclusively expressed in tip cells. Tip cells are specialized nonproliferating endothelial cells that form numerous filopodia and guide endothelial cell sprouting during angiogenesis (37) . Tip cell differentiation is dependent on VEGF/VEGFR and Notch signaling pathways (38, 39) . Several tip cell markers, including VEGFR2, endocan/ESM1, and angiopoietin 2, are generally upregulated in tumor vessels and were identified in our analysis of genes associated with vascular abnormality in glioblastoma (7, 40, 41) . The enrichment of tip cell-associated genes in tumor vessels may be connected to a high expression of VEGF in the tumor microenvi- independent experiments were analyzed by mass spectrometry for protein identification by LC-Orbitrap MS/MS at the Mass Spectrometry-Based Proteomics Facility, Science for Life Laboratory (SciLifeLab), Uppsala University. Protein identifications were obtained by a database search using the quantitation software MaxQuant 1.5.1.2. Proximity ligation assay. PLA was performed using the Duolink II kit (Sigma-Aldrich, DUO92104) according to a standard protocol at the PLA Proteomics Facility, SciLifeLab, Uppsala University. Briefly, HDBECs were incubated with mouse anti-human CD93 (MBL Life Science, D198-3) and goat anti-human MMRN2 (Santa Cruz Biotechnology, sc54021) primary antibodies or with rabbit anti-human CD93 (HPA, HPA009300) and mouse anti-human β 1 integrin (12G10, Abcam, ab30394) or mouse anti-human α 5 β 1 integrin (clone JBS5, Millipore, mab1969) primary antibodies. Cells were then incubated with specific PLA secondary probes. Actin and nuclei were detected by Alexa Fluor 488-phalloidin and Hoechst, respectively. Single primary antibodies with PLA probes and PLA probes without primary antibodies were included as negative controls. The PLA signal was quantified in 5 different areas of the cell monolayer using Duolink ImageTool software.
siRNA transfections. HDBECs were incubated with scrambled control siRNA or siRNA to CD93 (Hs_CD93_1 and Hs_CD93_2) or siRNA to MMRN2 (Hs_MMRN2_3 and Hs_MMRN2_6) (FlexiTube, Qiagen) at a concentration of 2 nM in a mixture of 20% Opti-MEM (Life Technologies) in endothelial cell medium supplemented with 30 μl/ml Lipofectamine RNAiMAX (Life Technologies) for 4-6 hours, after which the medium was replaced with fresh medium. Experiments were performed at day 2-3 after siRNA transfection.
Lentivirus production. For knockdown of CD93 or MMRN2, shRNA sequences targeting either of the genes were subcloned under the control of the H1 promoter into pBMN (EF1a-GFP-Puro) vectors. The shRNA sequence targeting CD93 is CAGGATTGTGTCAA-CACTCTA, and the sequence targeting MMRN2 is CAGCTTGTAT-CAGACATGGTA. This vector contains GFP for visualization and the puromycin resistance gene as a selection marker. Lentivirus particles were produced as previously described (50) .
Generation of CD93-WT HDMECs was performed as previously described (11) . Briefly, cDNA sequences for human CD93 (WT-CD93) were designed and purchased from GenScript. These sequences contain silent mutations in the regions where the CD93 siRNA sequences used in this study bind. The sequences were subcloned into a third-generation self-inactivating lentiviral vector together with coding sequences for GFP and puromycin to generate pBMN (CD93 WT).
Western blot. HDBECs were lysed in NuPAGE LDS Sample buffer under reducing or nonreducing conditions, according to the primary antibody manufacturer's recommendations. The samples were separated onto a 4%-12% Bis-Tris gel (Life Technologies) and blotted to a nitrocellulose membrane (Immobilon) . To analyze proteins secreted or cleaved from endothelial cells, conditioned medium derived from HDBECs maintained for 24 hours in EBM media supplemented with 1% FBS was collected, cell debris were removed by centrifugation, and 25 μg of total protein was separated onto a gel. The membranes were blocked and probed with anti-human CD93 (HPA, HPA009300), anti-human β 1 integrin (K20, Santa Cruz Biotechnology, sc18887), anti-human CD93 (MBL Life Science, D198-3), anti-human MMRN2 (Santa Cruz Biotechnology, sc54021), or anti-human β 1 integrin (12G10, Abcam, ab30394) or with anti-human β-actin (Santa Cruz Biotechnology, sc-1615) followed by appropriate horseradish peroxi-β 1 Integrin is important for filopodia formation, and basal filopodia have recently been shown to regulate organization of fibronectin into pillars between germ layers (43) . We found that CD93 colocalized with α 5 β 1 integrins in endothelial filopodia and identified CD93 as a novel regulator of β 1 integrin activation during tumor angiogenesis. Knockdown of either CD93 or MMRN2 led to a striking decrease in β 1 integrin activation in endothelial cells in vitro. Similarly, CD93 deficiency reduced β 1 integrin activation in murine GL261 glioma tumor vessels in vivo. Inhibition of integrin activation decreases angiogenesis and reduces tumor growth in several models (44, 45) , consistent with our observation of deficient integrin activation and decreased tumor growth observed in CD93
-/-mice. Fibronectin-binding integrins are required for assembly of soluble fibronectin into fibers, and α 5 β 1 integrin is the main integrin serving this function (21, 46, 47) . Consistent with an important role of α 5 β 1 integrin in fibronectin fibrillogenesis, siRNA knockdown or deficiency of either CD93 or MMRN2 in endothelial cells resulted in disruption of the fibronectin fibrillar network formation in vitro. In vivo, the fibronectin fibrillary network associated with the vasculature was disrupted during tumor angiogenesis in GL261 gliomas implanted intracranially in CD93 -/-mice. Fibronectin fibrillogenesis promotes vascular maturation during brain angiogenesis, which may explain the loss of vascular integrity and functionality in GL261 tumors noted in CD93 -/-mice (11). This suggests that inhibition of the interaction between CD93 and MMRN2 may lead to disruption of vascular integrity in tumors, representing a new target for pharmaceutical intervention. Above all, we have uncovered a novel CD93/MMRN2/β 1 integrin/ fibronectin signaling axis that orchestrates tumor angiogenesis and vascular stability in cancer.
Methods
Detailed information is given in the Supplemental Methods.
Tumor cell and primary endothelial cell culture. GL261 glioma cells (a gift from Geza Safrany, National Research Institute for Radiobiology and Radiohygiene, Budapest, Hungary) were cultured in DMEM (Life Technologies) supplemented with 10% FBS (Sigma-Aldrich) at 37°C and 5% CO 2 /95% air in a humidified chamber.
Human dermal microvascular endothelial cells (HDMECs) or human dermal blood endothelial cells (HDBECs) (PromoCell) were cultured in gelatin-coated culture dishes in Endothelial Cell Basal Medium with full supplements (PromoCell, EBM-MV2) at 37°C and 5% CO 2 /95% air in a humidified chamber.
Primary mouse brain endothelial cells were isolated from 12-weekold C57BL/6 WT or CD93 -/-mice as previously described (48) .
Mycoplasma test was routinely performed in all cell cultures used in this study.
Mice. CD93 -/-mice (49) and heterozygous and WT littermates were bred in house. C57BL/6 WT mice were purchased from Taconic M&B.
Coimmunoprecipitation and mass spectrometry analysis. Coimmunoprecipitation to identify CD93-interacting proteins was performed using the Pierce coimmunoprecipitation kit (Thermo Fisher Scientific) according to the manufacturer's instructions. Briefly, total protein extract obtained from subconfluent HDMECs was immunoprecipitated with mouse anti-human CD93 antibody (MBL Life Science, D198-3) or negative control mouse IgG (Santa Cruz Biotechnology, sc-2025 Tissue microarray and image analysis. Vascular expression of MMRN2 and fibronectin was scored in tissue microarrays containing duplicate tissue cores per sample (1 mm diameter) of 235 samples of human low-grade (WHO grade II, n = 65) and high-grade (WHO grade III, n = 29; WHO grade IV, n = 69) gliomas of various histologic subtypes, and nontumor brain tissue used as control (n = 2). Immunohistochemical staining was performed as previously described (52) using antibodies recognizing MMRN2 (HPA020741, Atlas Antibodies) and fibronectin (HPA027066, Atlas Antibodies) with DAB as a substrate. The frequency of positively stained vessels was scored in a blinded fashion by 2 researchers individually on a scale from 0 to 3 (0 = no vessels stained, 1 = minority of vessels stained, 2 = majority of vessels stained, 3 = strong staining in the majority of vessels). Data are shown as average of 2 individual scorings.
Image analysis. Image analysis was performed using ImageJ software. For the quantification of retinal parameters, migration of vessels was analyzed by measurement of the radial distance from the optic nerve head to the vascular front at the retinal periphery in at least 4 mice per genotype. The number of filopodia was counted per 100 μm of leading endothelial vessel membrane under ×63 magnification confocal micrographs. The sprouting front length was measured from the tip to the base of the sprout in at least 4 randomly selected front areas per retina and at least 4 mice per genotype; values represent the relative sprout length normalized to the migrating front length of each field used in the analysis. For the quantification of filopodia formation in control or MMRN2-and CD93-silenced endothelial cells, dase-labeled secondary antibodies. A representative blot image of at least 3 independent experiments is shown.
RNA extraction and quantitative PCR. RNA from control or siRNAtreated endothelial cells as well as tumor and nontumor brain tissue was extracted using the RNeasy Plus Mini Kit (Qiagen). Total RNA was transcribed using Superscript III reverse transcriptase in 20 μl total volume containing 250 ng of random hexamers and 40 units of RNase OUT inhibitor (Life Technologies). mRNA expression of CD93, MMRN2, and fibronectin was quantified relative to HPRT by realtime PCR in duplicate reactions per sample with 0.25 μM forward and reverse primer in SYBR Green PCR Master Mix (Life Technologies). Primer sequences are listed in Supplemental Methods.
Inhibitors. Inhibition of de novo protein synthesis of control or siMMRN2-transfected cells was performed using 50 μg/ml cycloheximide (Sigma Aldrich, 66-81-9). Cells were lysed at different time points after treatment (30, 60, and 240 minutes). Proteasome inhibition was performed using 20 μM lactacystin during 8 hours in control and siMMRN2-transfected cells. Inhibition of lysosomal protein degradation was performed using 10 mM NH 4 Cl during a period time of 18 hours in control and siMMRN2-transfected cells. Subsequently, cells were harvested, and cellular CD93 protein stability was assessed by Western blot analysis.
Migration assay. A double-sided wound was produced on a confluent HDBEC monolayer and maintained in EBM supplemented with 10% FBS. At 2, 4, and 6 hours after the scratch, images were taken of 4 different fields along the scratch, covering more than 90% of the initial cell-depleted area. The cell-free area for each field was calculated using ImageJ software (NIH), and cell migration (wound closure) was expressed as a percentage of the cell-free area at time point 0. Alternatively, at 6 or 8 hours after wounding, the cells were fixed for immunolabeling and confocal microscopy analysis. Rescue experiments were performed using 2-well culture inserts (ibidi, 80209). A representative image of each condition in at least 3 independent experiments is shown.
Embryoid body culture. Mouse embryonic stem (ES) cell culture and formation of embryoid bodies (EBs) was performed as previously described (51) and detailed in Supplemental Methods. Briefly, cultured ES cells were aggregated in hanging drops in order to form EBs and subsequently placed on 8-well chamber slides (2D EB culture) or between 2 layers of a collagen I gel (3D EB culture). EBs were cultured in the presence of 30 ng/ml VEGF-A165. Medium was changed every other day, and, at day 14, EBs were fixed in 4% paraformaldehyde and processed for whole-mount immunofluorescence. A representative image of at least 5 individual EBs is shown. In specific experiments, ES cells were transduced with lentiviruses with CD93 or MMRN2 shRNA construct or empty vector as control. GFP-positive cells were isolated by FACS. Transduced ES cells were cultured as described above.
Immunofluorescent staining of endothelial cells. siRNA-transfected HDBECs or mouse brain endothelial cells were stained with anti-CD93 (MBL Life Science, D198-3), anti-CD93 (HPA, HPA009300), anti-MMRN2 (Santa Cruz Biotechnology, sc54021), anti-fibronectin (Abcam, ab2413), anti-fibronectin (Sigma-Aldrich, F7387), anti-β 1 integrin (12G10, Abcam, ab30394), anti-α 5 β 1 integrin (clone JBS5, Millipore, mab1969), anti-α v β 3 integrin (Millipore, MAB1976), antip-FAK (Y397, Abcam, ab39967), anti-α-tubulin (Abcam, ab52866), anti-vimentin (Abcam, ab92547), anti-vWF (Dako, A0082), and anticaveolin-1 (Cell Signaling Technology, CST3238). Cells were subsequently incubated with appropriate Alexa Fluor-conjugated second-jci.org
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